Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Yunfeng Capital/Alibaba Wins $1.6 Billion Takeover Battle for iKang Healthcare

publication date: Jun 8, 2016

According to ChinaMoneyNetwork.com, Yunfeng Capital, the investment vehicle backed by Alibaba's Jack Ma, has won the takeover battle for iKang Healthcare, a chain of private China healthcare clinics. The other two bidders for the company --Meinian Onehealth and management -- have withdrawn their bids, said the site, leaving Yunfeng as the only contender. The question now becomes whether iKang will be absorbed into Alibaba's mobile health platform. However, so far, iKang has not made any official announcement that Yunfeng won the takeover battle. More details....

Stock Symbols: (NYSE: BABA) (NSDQ: KANG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital